Loading...
OTCM
SEOVF
Market cap34mUSD
Jul 09, Last price  
0.09USD
1D
-2.32%
1Q
-32.71%
Name

Sernova Corp

Chart & Performance

D1W1MN
OTCM:SEOVF chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
10.72%
Rev. gr., 5y
%
Revenues
0k
Net income
-16m
L-51.10%
-1,257,000-3,592,000-2,753,000-1,468,000-1,846,000-2,028,000-2,568,000-2,003,000-2,746,000-2,859,000-2,499,622-2,639,000-3,699,000-3,971,000-5,321,000-6,966,000-24,421,000-38,998,000-32,192,000-15,741,351
CFO
-11m
L-42.28%
-758,631-2,225,322-1,249,178-574,196-825,729-901,179-1,569,040-1,205,046-1,704,561-2,164,790-2,553,055-2,740,359-3,916,011-4,192,390-3,939,199-6,843,744-14,421,398-30,339,117-18,896,313-10,906,501

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sernova Corp. is a Canadian clinical-stage enterprise specializing in the development and commercialization of groundbreaking regenerative medicine therapies. Its core endeavors revolve around its proprietary Cell Pouch system and associated technologies, which encompass specialized therapeutic cells and mechanisms for localized cellular immune protection. The Cell Pouch itself is an innovative medical device engineered to establish a highly vascularized tissue environment, crucial for the successful transplantation and engraftment of therapeutic cells. Once integrated, these cells are designed to secrete vital proteins or hormones, providing sustained treatment for a range of severe chronic conditions, including diabetes, hemophilia, and thyroid dysfunction. To bolster its research and development, Sernova maintains a collaborative partnership with AgeX Therapeutics, Inc. focused on generating immune-protected therapeutic cells, and an ongoing research agreement with the University of Miami to further refine its Cell Pouch cell therapy platform. Established in 1998, Sernova Corp. maintains its corporate headquarters in London, Canada.
IPO date
Apr 15, 1999
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑102024‑102023‑102022‑102021‑102020‑102019‑102018‑102017‑102016‑10
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT